c-MYC
Use
c-MYC is a proto-oncogene that produces short-lived nuclear phosphoprotein. Overexpression of c-MYC is implicated in the etiology of a variety of hematopoietic tumors. Dual overexpression of BCL2 and MYC oncoproteins is associated with unfavorable outcomes in diffuse large B cell lymphoma (DLBCL).
Special Instructions
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Limitations
The performance and interpretation of results may be influenced by the pre-analytical variables, such as specimen handling, fixation time, or tissue source. Certain factors, like improper handling or suboptimal fixation, may lead to inaccurate or non-reproducible results.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fixed (Non-FFPE))
Volume
Not provided
Minimum Volume
Not provided
Container
Fresh Tissues: Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours PREFERRED)
Storage Instructions
15°C to 25°C
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours |